Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Myelodysplastic Syndromes 3Mycosis Fungoides 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2Leukemia, Myeloid, Acute 2Glioblastoma 2Breast Neoplasms 2Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neurofibrosarcoma 1Neurofibromatosis 1 1Neoplasms 1Multiple Myeloma 1Mesothelioma, Malignant 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, B-Cell 1Lung Neoplasms 1Liver Neoplasms 1Immunoblastic Lymphadenopathy 1Gliosarcoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Biochemically Recurrent Prostate Carcinoma 1

Interventions

Temozolomide 48Radiotherapy 26Radiation 13Chemotherapy, Adjuvant 9O(6)-benzylguanine 8Irinotecan 8Carmustine 8Surgical Procedures, Operative 7Magnetic Resonance Spectroscopy 6Erlotinib Hydrochloride 6motexafin gadolinium 5Radiotherapy, Intensity-Modulated 5Imatinib Mesylate 5sargramostim 4Radiotherapy, Conformal 4Hydroxyurea 4Gene Expression Profiling 4lonafarnib 3Radiosurgery 3Immunohistochemistry 3Genetic Therapy 3Filgrastim 3Drug Therapy 32,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 3vandetanib 2tipifarnib 2temsirolimus 2cediranib 2aldesleukin 2Vorinostat 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Gliosarcoma × Photons × Clear all
NCT07422363 2026-05-13

Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma

National Cancer Institute (NCI)

Phase 1 Not yet recruiting
30 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡